Nanoscribe and Advanced BioMatrix have joined forces to pioneer the field of bioprinting with the launch of four advanced bioresins tailored for Two-Photon Polymerization (2PP) based 3D printing.
Otsuka cuts development for AVP-786 following Phase III flop – Pharmaceutical Technology
Otsuka Pharmaceuticals ended clinical development for AVP-786 for agitation associated with Alzheimer’s disease following a negative Phase III readout. Credit: SOPA Images via Getty Images.